Literature DB >> 11761088

Use of desmopressin and erythropoietin in an anaemic Jehovah's Witness patient with severely impaired coagulation capacity undergoing stentless aortic valve replacement.

S Beholz1, J Liu, R Thoelke, C Spiess, W Konertz.   

Abstract

Cardiac surgery in Jehovah's Witness patients remains a challenge in the presence of concomitant congenital or acquired coagulation disorders and anaemia. We report a case of a 66-year-old female Jehovah's Witness suffering from severe calcified aortic valve stenosis requiring aortic valve replacement. The anaemic patient suffered from concomitant platelet dysfunction and deficiency of factors V and VII due to gammopathy of immunoglobulin G. The patient was preoperatively treated with recombinant erythropoietin in combination with folic acid and iron, which resulted in an increase of the haematocrit from 0.335 to 0.416 after 22 days of treatment. Haemostasis was improved by high dose aprotinin and additional desmopressin, which could be demonstrated to be effective by a preoperative test. The patients intra- and postoperative course was uneventful, her total chest tube loss was 130 ml, and she was able to be discharged without the need of any blood transfusions. The beneficial properties of erythropoietin and desmopressin in Jehovah's Witness patients are discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11761088     DOI: 10.1177/026765910101600608

Source DB:  PubMed          Journal:  Perfusion        ISSN: 0267-6591            Impact factor:   1.972


  3 in total

1.  Preanesthetic Assessment of the Jehovah's Witness Patient.

Authors:  Eric S Lin; Alan D Kaye; Amir R Baluch
Journal:  Ochsner J       Date:  2012

Review 2.  Review of abdominal solid organ transplantation in Jehovah's Witness patients.

Authors:  Rodrigo S Figueiredo; Rohan G Thakkar; Paul R Ainley; Colin H Wilson
Journal:  World J Transplant       Date:  2019-09-26

Review 3.  Preoperative recombinant human erythropoietin in anemic surgical patients.

Authors:  Terri G Monk
Journal:  Crit Care       Date:  2004-06-14       Impact factor: 9.097

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.